Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Paterniti, Irene ^a   Melani, Alessia ^b   Cipriani, Sara ^b   Corti, Francesca ^b   Mello, Tommaso ^b   Mazzon, Emanuela ^c   Esposito, Emanuela ^a,c   Bramanti, Placido ^c   Cuzzocrea, Salvatore ^a,c   Pedata, Felicita ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; FAS LIGAND; PEPTIDES AND PROTEINS; PROTEIN BAX; PROTEIN BCL 2; PROTEIN PAR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2 (4 (2 CARBOXYETHYL)PHENETHYLAMINO) 5' N ETHYLCARBOXAMIDOADENOSINE; 2-(4-(2-CARBOXYETHYL)PHENETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; 5 AMINO 7 (2 PHENYLETHYL) 2 (2 FURYL)PYRAZOLO(4,3 E) 1,2,4 TRIAZOLO(1,5 C)PYRIMIDINE; 5-AMINO-7-(2-PHENYLETHYL)-2-(2-FURYL)PYRAZOLO(4,3-E)-1,2,4-TRIAZOLO(1,5-C)PYRIMIDINE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DAMAGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEMYELINATION; DRUG MECHANISM; IMMUNOHISTOLOGY; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SHORT COURSE THERAPY; SPINAL CORD INJURY; SYSTEMIC THERAPY; ANIMAL; DRUG EFFECT; INFLAMMATION; INFUSION PUMP; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; INFLAMMATION; INFUSION PUMPS, IMPLANTABLE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MOTOR ACTIVITY; PHENETHYLAMINES; PYRIMIDINES; SPINAL CORD; SPINAL CORD INJURIES; TRIAZOLES;

EID: 79953849292     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-31     Document Type: Article

References (67)

1. Maegele M, Riess P, Sauerland S, Bouillon B, Hess S, McIntosh TK, Mautes A, Brockmann M, Koebke J, Knifka J, Neugebauer EA. Characterization of a new rat model of experimental combined neurotrauma. Shock 2005, 23:476-481. 10.1097/01.shk.0000159929.87737.5c, 15834316.
2. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004, 15:415-436. 10.1016/j.nbd.2003.11.015, 15056450.
3. Hagg T, Oudega M. Degenerative and spontaneous regenerative processes after spinal cord injury. J Neurotrauma 2006, 23:264-280.
4. Linden J. Adenosine in tissue protection and tissue re generation. Mol Pharmacol 2005, 67:1385-1387. 10.1124/mol.105.011783, 15703375.
5. Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma 2004, 21:429-440. 10.1089/089771504323004575, 15115592.
6. Moreno-Flores MT, Avila J. The quest to repair the damaged spinal cord. Recent Pat CNS Drug Discov 2006, 1:55-63. 10.2174/157488906775245264, 18221191.
7. Bao F, DeWitt DS, Prough DS, Liu D. Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin. J Neuroscience Res 2003, 71:220-227.
8. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Min W, Di Paola R, Muia C, Li JH, Esposito E, Bramanti P, Xu W, Massuda E, Zhang J, Wang ZQ. Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma. J Pharmacol Exp Ther 2006, 319:127-138. 10.1124/jpet.106.108076, 16825529.
9. Genovese T, Mazzon E, Mariotto S, Menegazzi M, Cardali S, Conti A, Suzuki H, Bramanti P, Cuzzocrea S. Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. J Neurosurgery 2006, 4:145-153.
10. Glaser J, Gonzalez R, Sadr E, Keirstead HS. Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury. J Neuroscience Res 2006, 84:724-734.
11. Cassada DC, Tribble CG, Young JS, Gangemi JJ, Gohari AR, Butler PD, Rieger JM, Kron IL, Linden J, Kern JA. Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J Trauma 2002, 53:225-229. discussion 229-231, 10.1097/00005373-200208000-00005, 12169926.
12. Reece TB, Davis JD, Okonkwo DO, Maxey TS, Ellman PI, Li X, Linden J, Tribble CG, Kron IL, Kern JA. Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma. J Surg Res 2004, 121:130-134. 10.1016/j.jss.2004.04.006, 15313386.
13. Li Y, Oskouian RJ, Day YJ, Rieger JM, Liu L, Kern JA, Linden J. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience 2006, 141:2029-2039. 10.1016/j.neuroscience.2006.05.014, 16777350.
14. Genovese T, Melani A, Esposito E, Mazzon E, Di Paola R, Bramanti P, Pedata F, Cuzzocrea S. The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock 2009, 32:578-585. 10.1097/SHK.0b013e3181a20792, 19295488.
15. Genovese T, Melani A, Esposito E, Paterniti I, Mazzon E, Di Paola R, Bramanti P, Linden J, Pedata F, Cuzzocrea S. Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. J Biol Regul Homeost Agents 2010, 24:73-86.
16. Yin KJ, Kim GM, Lee JM, He YY, Xu J, Hsu CY. JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis 2005, 20:881-889. 10.1016/j.nbd.2005.05.026, 16005241.
17. Chen JF, Pedata F. Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des 2008, 14:1490-1499. 10.2174/138161208784480126, 18537672.
18. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999, 19:9192-9200.
19. Phillis JW. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 1995, 705:79-84. 10.1016/0006-8993(95)01153-6, 8821736.
20. Melani A, Pantoni L, Bordoni F, Gianfriddo M, Bianchi L, Vannucchi MG, Bertorelli R, Monopoli A, Pedata F. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 2003, 959:243-250. 10.1016/S0006-8993(02)03753-8, 12493612.
21. Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 2006, 1073-1074:470-480. 10.1016/j.brainres.2005.12.010, 16443200.
22. Melani A, Cipriani S, Vannucchi MG, Nosi D, Donati C, Bruni P, Giovannini MG, Pedata F. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 2009, 132:1480-1495. 10.1093/brain/awp076, 19359287.
23. McAdoo DJ, Robak G, Xu GY, Hughes MG. Adenosine release upon spinal cord injury. Brain Res 2000, 854:152-157. 10.1016/S0006-8993(99)02333-1, 10784116.
24. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994, 46:143-156.
25. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surgical neurology 1978, 10:38-43.
26. Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F. Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport 1999, 10:687-691. 10.1097/00001756-199903170-00005, 10208531.
27. Corsi C, Melani A, Bianchi L, Pedata F. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 2000, 11:2591-2595. 10.1097/00001756-200008030-00048, 10943728.
28. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 2006, (23):635-59. 10.1089/neu.2006.23.635, 16689667.
29. Bronstein JM, Chen K, Tiwari-Woodruff S, Kornblum HI. Developmental expression of OSP/claudin-11. J Neurosci Res 2000, 60:284-290. 10.1002/(SICI)1097-4547(20000501)60:3<284::AID-JNR2>3.0.CO;2-T, 10797530.
30. Cassada DC, Tribble CG, Long SM, Kaza AK, Linden J, Rieger JM, Rosin D, Kron IL, Kern JA. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg 2002, 74:846-849. 10.1016/S0003-4975(02)03793-1, 12238849.
31. Sebastiao AM, Ribeiro J. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br J Pharmacol 2009, 158:15-22. 10.1111/j.1476-5381.2009.00157.x, 2795259, 19508402.
32. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004, 61:657-668. 10.1007/s00018-003-3319-x, 15052409.
33. Baptiste DC, Fehlings MG. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006, 23:318-334. 10.1089/neu.2006.23.318, 16629619.
34. Rokkas CK, Helfrich LR, Lobner DC, Choi DW, Kouchoukos NT. Dextrorphan inhibits the release of excitatory amino acids during spinal cord ischemia. Ann Thorac Surg 1994, 58:312-319. 10.1016/0003-4975(94)92200-4, 7915102.
35. Rokkas CK, Cronin CS, Nitta T, Helfrich LR, Lobner DC, Choi DW, Kouchoukos NT. Profound systemic hypothermia inhibits the release of neurotransmitter amino acids in spinal cord ischemia. J Thorac Cardiovasc Surg 1995, 110:27-35. 10.1016/S0022-5223(05)80006-6, 7609553.
36. Farooque M, Hillered L, Holtz A, Olsson Y. Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord. J Neurotrauma 1997, 14:63-69. 10.1089/neu.1997.14.63, 9048312.
37. Tator CH. Review of experimental spinal cord injury with emphasis on the local and systemic circulatory effects. Neurochirurgie 1991, 37:291-302.
38. Anderson DK, Hall ED. Pathophysiology of spinal cord trauma. Ann Emerg Med 1993, 22:987-992. 10.1016/S0196-0644(05)82739-8, 8503537.
39. Xiong Y, Rabchevsky AG, Hall ED. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J Neurochem 2007, 100:639-649. 10.1111/j.1471-4159.2006.04312.x, 17181549.
40. Miyazaki N, Nakatsuka T, Takeda D, Nohda K, Inoue K, Yoshida M. Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones. Pflugers Arch 2008, 457:441-451. 10.1007/s00424-008-0542-1, 18584206.
41. Jones PA, Smith RA, Stone TW. Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 1998, 85:229-237. 10.1016/S0306-4522(97)00613-1, 9607714.
42. Jones PA, Smith RA, Stone TW. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res 1998, 800:328-335. 10.1016/S0006-8993(98)00540-X, 9685693.
43. Pintor A, Quarta D, Pèzzola A, Reggio R, Popoli P. SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur J Pharmacol 2001, 421:177-180. 10.1016/S0014-2999(01)01058-5, 11516434.
44. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pè zzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002, 22:1967-1975.
45. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N, Chen XY, Xiong RP, Liu P, Zhao Y, Shen HY, Zhu PF, Chen JF. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 2010, 30:5802-5810. 10.1523/JNEUROSCI.0268-10.2010, 20410132.
46. Zocchi C, Ongini E, Ferrara S, Baraldi PG, Dionisotti S. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 1996, 117:1381-1386. 1909468, 8730729.
47. Wirkner K, Gerevich Z, Krause T, Gü nther A, Kö les L, Schneider D, Nö renberg W, Illes P. Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology 2004, 46:994-1007. 10.1016/j.neuropharm.2004.01.008, 15081796.
48. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 2007, 83:310-331. 10.1016/j.pneurobio.2007.09.002, 18023959.
49. Monopoli A, Casati C, Lozza G, Forlani A, Ongini E. Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther 1998, 285:9-15.
50. Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, Chen JF. Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 2004, 10:1081-1087. 10.1038/nm1103, 15448683.
51. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003, 65:493-501. 10.1016/S0006-2952(02)01548-4, 12566076.
52. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006, 203:2639-2648. 10.1084/jem.20061097, 2118143, 17088433.
53. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 2006, 177:2765-2769.
54. Mirabet M, Herrera C, Cordero OJ, Mallol J, Lluis C, Franco R. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 1999, 112:491-502.
55. Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 2000, 129:2-11. 10.1038/sj.bjp.0703045, 1621134, 10694196.
56. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998, 125:379-387. 10.1038/sj.bjp.0702040, 1565610, 9786512.
57. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129:26-33. 10.1053/j.gastro.2005.05.032, 16012931.
58. Choukè r A, Thiel M, Lukashev D, Ward JM, Kaufmann I, Apasov S, Sitkovsky MV, Ohta A. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med 2008, 14:116-123. 2156187, 18163162.
59. Howe CL, Bieber AJ, Warrington AE, Pease LR, Rodriguez M. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis 2004, 15:120-131. 10.1016/j.nbd.2003.09.002, 14751777.
60. Jurewicz A, Matysiak M, Andrzejak S, Selmaj K. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia 2006, 53:158-166. 10.1002/glia.20249, 16206163.
61. Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G, Raine CS. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol 1999, 155:1433-1438. 10.1016/S0002-9440(10)65456-9, 1866971, 10550297.
62. Matute C, Sá nchez-Gó mez MV, Martí nez-Millá n L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 1997, 94:8830-8835. 10.1073/pnas.94.16.8830, 23152, 9238063.
63. Matute C, Alberdi E, Ibarretxe G, Sá nchez-Gó mez MV. Excitotoxicity in glial cells. Eur J Pharmacol 2002, 447:239-246. 10.1016/S0014-2999(02)01847-2, 12151015.
64. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998, 4:291-297. 10.1038/nm0398-291, 9500601.
65. Back SA. Perinatal white matter injury: the changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev 2006, 12:129-140. 10.1002/mrdd.20107, 16807910.
66. Rosin C, Bates TE, Skaper SD. Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms. J Neurochem 2004, 90:1173-1185. 10.1111/j.1471-4159.2004.02584.x, 15312172.
67. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. Faseb J 2000, 14:2065-2074. 10.1096/fj.99-0508com, 11023991.